Lorenza Landi
A5063424146- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Cancer Mechanisms and Therapy
- Lung Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- MicroRNA in disease regulation
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Computational Drug Discovery Methods
- Prostate Cancer Treatment and Research
- Cancer-related molecular mechanisms research
- Chromatin Remodeling and Cancer
- Cancer therapeutics and mechanisms
- PI3K/AKT/mTOR signaling in cancer
- Melanoma and MAPK Pathways
- Pancreatic and Hepatic Oncology Research
- Mechanisms of cancer metastasis
- Peptidase Inhibition and Analysis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Brain Metastases and Treatment
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2025
Istituti Fisioterapici Ospitalieri
2023-2025
Instituto Nazionale Tumori Regina Elena
2020-2024
Rehabilitation Foundation
2024
Fondazione IRCCS Istituto Nazionale dei Tumori
2020-2023
National Cancer Institute
2023
Azienda Unità Sanitaria Locale Della Romagna
2017-2021
University of Bologna
1993-2021
Ospedale Santa Maria
2017-2021
Policlinico S.Orsola-Malpighi
2021
Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether PD-1/PD-L1 differently expressed oncogene-addicted NSCLC. We analysed a cohort of 125 NSCLC patients, including 56 EGFR mutated, 29 KRAS 10 ALK translocated 30 EGFR/KRAS/ALK wild type. PD-L1 PD-1 expression were assessed by immunohistochemistry. All cases with moderate or strong staining (2+/3+) >5% tumour cells considered as...
MET-deregulated NSCLC represents an urgent clinical need because of unfavorable prognosis and lack specific therapies. Although recent studies have suggested a potential role for crizotinib in patients harboring MET amplification or exon 14 mutations, no conclusive data are currently available. This study aimed at investigating activity ROS1 alterations.Patients with pretreated advanced evidence rearrangements (cohort A) deregulation (amplification, ratio MET/CEP7 >2.2 cohort B) were treated...
Background Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatment line). Whether such relationship is causative or associative matter of debate. Methods We present the outcomes analysis according baseline (prior ICI initiation) putative immune-modulatory effects...
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRASG12C-mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis 424 patients with non-small cell lung cancer (NSCLC), we identified and validated coalterations KEAP1, SMARCA4, CDKN2A as major independent determinants inferior clinical outcomes KRASG12Ci monotherapy. Collectively, comutations these three tumor suppressor genes segregated into distinct prognostic subgroups captured ∼50% those early...
<h3>Background</h3> Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. <h3>Methods</h3> Pretreated non-squamous (cohort A) and squamous B) NSCLCs included the Italian Expanded Access Program were evaluated for nivolumab efficacy according BoM. <h3>Results</h3> Cohort A accounted 1588 patients...
In metastatic colorectal cancer (mCRC), KRAS is the only validated biomarker used to select patients for administration of epidermal growth factor receptor (EGFR)-targeted therapies. To identify additional predictive markers, we investigated importance HER2, primary EGFR dimerisation partner, in this particular disease. We evaluated HER2 gene status by fluorescence situ hybridisation (FISH) 170 wild-type mCRC treated with cetuximab or panitumumab. Depending on copy number status, showed...
To investigate whether copy number gain of MET or hepatocyte growth factor (HGF) affect trastuzumab sensitivity in HER2-positive metastatic breast cancer (MBC). We analysed 130 MBC treated with trastuzumab-based therapy. and HGF gene numbers (GCN) were assessed by fluorescence situ hybridisation (FISH) primary samples. Receiver operating characteristic analysis was applied to find the best cutoff point for both GCN. FISH-positive cases (N=36, mean ⩾3.72) had a significantly higher failure...
Background The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression. Methods We present the analysis according to baseline body mass index (BMI) BMI variation a large cohort metastatic NSCLC with expression ≥50%, first line pembrolizumab. also evaluated control treated platinum-based...
Study Type – Therapy (retrospective cohort) Level of Evidence 2b What's known on the subject? and What does study add? Various targeted agents with differing mechanisms action toxicity profiles have now been approved for treatment advanced RCC. However, optimal use these remains a challenge. Since approval sorafenib sunitinib, many patients treated two tyrosine kinase inhibitors (TKIs) in sequence, current evidence suggesting that this approach is associated continued clinical benefit,...
microRNAs (miRNAs) can act as oncosuppressors or oncogenes, induce chemoresistance chemosensitivity, and are major posttranscriptional gene regulators. Anaplastic lymphoma kinase (ALK), EGF receptor (EGFR), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) drivers of non-small cell lung cancer (NSCLC). The aim this study was to assess the miRNA profiles NSCLCs driven by translocated ALK, mutant EGFR, KRAS find driver-specific diagnostic prognostic signatures. A total 85...
Abstract There is the urgent need to study effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective with 30 days observation was carried out assess clinical outcomes in 88 patients hospitalized Covid-19 pneumonia and treated canakinumab (300 mg sc). Median time from diagnosis by viral swab administration 7.5 (range 0–30, IQR 4–11). PaO 2 /FiO increased 160 53–409, 122–210) at baseline 237 72–533, 158–331) day 7 after treatment ( p < 0.0001)....
Background: Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related deaths worldwide. Epidermal Growth Factor Receptor (EGFR)-mutated patients usually benefit from TKIs treatment, but a significant portion show unresponsiveness due to resistance mechanisms. We investigated role TP53 mutations in predicting survival and response EGFR-TKIs EGFR-mutated NSCLC patients, confirm, on an independent case series, our previous results. Methods: An retrospective cohort study was...
To stratify the prognosis of patients with programmed cell death-ligand 1 (PD-L1) ≥ 50% advanced non-small-cell lung cancer (aNSCLC) treated first-line immunotherapy.Baseline clinical prognostic factors, neutrophil-to-lymphocyte ratio (NLR), PD-L1 tumour expression level, lactate dehydrogenase (LDH) and their combination were investigated by a retrospective analysis 784 divided between statistically powered training (n = 201) validation 583) cohorts. Cut-offs explored receiver operating...
Abstract Purpose: The aims of the present study were to evaluate clinical activity and pharmacodynamic profile novel schedule a single i.v. standard dose cyclophosphamide (CTX) immediately followed by an oral metronomic CTX regimen with celecoxib (CXB) dexamethasone (DEX) in advanced hormone-refractory prostate cancer patients. Experimental Design: Twenty-eight patients (68% docetaxel-resistant) received 500 mg/m2 bolus on day 1 and, from 2, 50 mg/day p.o. plus 200 mg/twice CXB DEX until...